Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.12 USD | -0.98% | -4.62% | -15.60% |
Financials (USD)
Sales 2024 * | 274M | Sales 2025 * | 180M | Capitalization | 1.47B |
---|---|---|---|---|---|
Net income 2024 * | -316M | Net income 2025 * | -409M | EV / Sales 2024 * | 2.93 x |
Net cash position 2024 * | 663M | Net cash position 2025 * | 415M | EV / Sales 2025 * | 5.84 x |
P/E ratio 2024 * |
-4.48
x | P/E ratio 2025 * |
-3.56
x | Employees | 577 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.18% |
Latest transcript on Arcus Biosciences, Inc.
1 day | -0.98% | ||
1 week | -4.62% | ||
Current month | +5.84% | ||
1 month | +9.44% | ||
3 months | -17.46% | ||
6 months | +14.65% | ||
Current year | -15.60% |
Managers | Title | Age | Since |
---|---|---|---|
Juan Jaen
FOU | Founder | 66 | 14-12-31 |
Terry Rosen
CEO | Chief Executive Officer | 65 | 14-12-31 |
Robert Goeltz
DFI | Director of Finance/CFO | 51 | 20-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Terry Rosen
CEO | Chief Executive Officer | 65 | 14-12-31 |
Kathryn Falberg
BRD | Director/Board Member | 63 | 17-09-17 |
Yasunori Kaneko
BRD | Director/Board Member | 69 | 15-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.88% | 11 M€ | -6.03% | - | |
0.28% | 25 M€ | -2.72% | - | |
0.12% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 16.12 | -0.98% | 560,498 |
24-05-23 | 16.28 | -2.81% | 796,332 |
24-05-22 | 16.75 | -2.84% | 675,151 |
24-05-21 | 17.24 | +2.74% | 531,073 |
24-05-20 | 16.78 | -0.71% | 483,027 |
Delayed Quote Nyse, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.60% | 1.47B | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- RCUS Stock